Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Araris Biotech AG Announces Strategic Investment with Samsung Ventures
Tuesday, April 11, 2023Araris Biotech AG a company pioneering a proprietary antibodydrug conjugate ADClinker technology today announced that Samsung Venture Investment Corporation an investment corporation established to promote the development of new technologies has inve...
CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy annual Meeting
Tuesday, April 11, 2023CANbridge Pharmaceuticals Inc a China and USbased global biopharmaceutical company committed to the research development and commercialization of transformative therapies to treat rare diseases and oncology announced that the American Society for Gen...
Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-1287, an Investigational Oral CDK9 Inhibitor for the Treatment of Ewing Sarcoma
Monday, April 10, 2023Sumitomo Pharma Oncology Inc a clinicalstage company focused on novel cancer therapeutics today announced the US Food and Drug Administration FDA granted Orphan Drug Designation for TP an investigational oral CDK inhibitor for the treatment of Ewing...
Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data
Monday, April 10, 2023Hillstream BioPharma Inc a biotechnology company developing a portfolio of therapeutic candidates targeting drug resistant and devastating cancers announced pharmacokinetic PK data of HSB supportive of its development strategy and preclinical data Th...
Tillotts Pharma AG announces the launch of Octasa® 1600 mg Tablets in Canada
Thursday, April 06, 2023Tillotts Pharma AG Tillotts part of the Japanese Zeria Group is pleased to announce the recent launch of Octasa mg mesalazine delayedrelease tablets as firstline treatment for moderately active ulcerative colitis UC in Canada The expansion of the Oc...
China's First Nectin-4 Targeted ADC 9MW2821 Clinical Progress Released
Thursday, April 06, 2023Mabwell an innovative biopharmaceutical company with the whole industry chain layout announced its Nectin targeted sitespecific ADC asset RD code MW demonstrated promising clinical data The preliminary data show positive therapeutic signals in solid...
Bora Pharmaceuticals and Celltrion partner to expand OSD capabilities in APAC market
Wednesday, April 05, 2023Bora Pharmaceuticals Co Ltd and Celltrion Asia Pacific Pte Ltd a subsidiary of Celltrion Group Inc have today announced their partnership to contract manufacture and commercialize a range of oral dosage form drugs OSD across the APAC region The range...
Abacus Medicine Pharma Services and Laboratoires CTRS Extend Partnership to Improve Access to Orphacol® in Spain
Tuesday, April 04, 2023Abacus Medicine Pharma Services AMPS and Laboratoires CTRS marketing authorization holder of Orphacol are proud to announce a strategic partnership that ensures continuous stock of Orphacol in Spain Furthermore the partnership means improved delivery...
Repairon Announces Completion of Dose-Finding Part of BioVAT-HF Phase 1/2 Trial in Advanced Heart Failure
Tuesday, April 04, 2023Repairon a clinicalstage German biotech company focused on developing a novel reparative treatment for heart failure together with the University Medical Center Gttingen UMG and the University Medical Center SchleswigHolstein UKSH Campus Lbeck as wel...
Alterity Therapeutics Enrolls First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Tuesday, April 04, 2023Alterity Therapeutics a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases today announced the first participant has been dosed in the United Kingdom in the Companys Phase clinical trial of ATH...
